The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
It’s not clear just how BrainCells’ BCI-540 works but the company claims the drug acts by way of promoting neurogenesis without an effect on serotonin neurotransmission. While SSRI’s also promote neurogenesis, a downstream effect believed to favorably impact mood and anxiety, they obviously...
This is a potentially interesting alternative to current ADHD stimulant treatment. There is, I believe, existing literature on the efficacy of nicotine patches in the treatment of severe,otherwise intractable ADHD in children, which would seem to support these results. Of course, much work remains to...
Don't bother listening to the May 6 audio presentation, as it is a useless waste of time. Just look at the pdf slide presentation, showing tapentadol IR to provide equivalent pain control to 10 or 15mg oxycodone, with reduced GI side effects, in treating acute bunionectomy pain and also arthritis...
Abbott’s Neuronal Nicotinic Receptor (NNR) partial agonist platform is an innovative target for ADHD and potentially other CNS disorders. The Phase II data on ABT-089 suggests efficacy for adult ADHD with good safety/tolerability. NNRs will not have the kind of effect size seen with stimulants...
Eli Lilly needs to find a compelling niche for Strattera since, in the treatment of ADHD, it is viewed as a less effective, though safer (because it cannot be abused), alternative to stimulants.
1. Effective treatment for ADHD 2. Well tolerated with few side effects 3. Help with smoking, a big problem in ADHD patients important 4. Advantage in not being Schedule II may be helpful
1. Important new finding given safety concerns raised about this and other treatmetns 2. Nice to have data back up what has long been done clinically 3. Stimulants still first line and lack of active comparator trial